188 related articles for article (PubMed ID: 15605666)
1. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
Sharma JC; Macnamara L; Hasoon M; Vassallo M
Int J Clin Pract; 2004 Nov; 58(11):1028-32. PubMed ID: 15605666
[TBL] [Abstract][Full Text] [Related]
2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
4. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of apomorphine in movement disorders.
Colosimo C; Merello M; Albanese A
Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
[TBL] [Abstract][Full Text] [Related]
6. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Clin Neuropharmacol; 1996 Jun; 19(3):193-201. PubMed ID: 8726538
[TBL] [Abstract][Full Text] [Related]
7. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
8. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
[TBL] [Abstract][Full Text] [Related]
9. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
11. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.
Tyne HL; Parsons J; Sinnott A; Fox SH; Fletcher NA; Steiger MJ
J Neurol; 2004 Nov; 251(11):1370-4. PubMed ID: 15592733
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Nutt JG; Carter JH
Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
[TBL] [Abstract][Full Text] [Related]
14. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine: North American clinical experience.
Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
[TBL] [Abstract][Full Text] [Related]
16. Acute challenge with apomorphine and levodopa in Parkinsonism.
Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
[TBL] [Abstract][Full Text] [Related]
17. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
18. [Apomorphine: a powerful ally in Parkinson's disease].
Alonso-Canovas A; Martínez-Castrillo JC
Rev Neurol; 2021 May; 72(9):323-332. PubMed ID: 33908619
[TBL] [Abstract][Full Text] [Related]
19. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
20. Rapid treatment of "wearing off" in Parkinson's disease.
Swope DM
Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]